Please input keywords
Collaboration Models
Advancing the development of innovative drugs through partnership
RenMice licensing
Drug licensing/co-development
Other flexible ways to collaborate
Disclosed Partners
As of June 30, 2022, Biocytogen has reached 16 RenMice licensing agreements and 28 drug co-development agreements with companies around the world, including several partnerships with MNCs. These collaborations aim to accelerate the development and commercialization of novel therapeutics that benefit patients.
Interested in partnering with us? Click or contact us at
Contact us